Biotech Calendar: Key Dates for October
BOSTON (TheStreet) -- The October biotech calendar is chock-full of potentially stock moving events, including a dozen drugs facing U.S. approval decisions.
More from Adam Feuerstein
Phase III or pivotal studies that could report results in October:
* Bristol-Myers(BMY_) Squibb's melanoma drug ipilimumab.
* Corcept Therapeutics'(CORT_) Corlux in Cushing's syndrome.
* Seattle Genetics'(SGEN_) brentuximab vedotin in anaplastic large cell lymphoma.
* Cyclacel Pharmaceuticals'(CYCC_) seliciclib in non-small cell lung cancer.
Oct. 1
FDA drug approval decision: Hospira'(HSP_) Dyloject for acute moderate-to-severe pain in adults.
FDA drug approval decisions: Johnson & Johnson(JNJ_) Nucynta for pain indications.
Oct. 4
FDA drug approval decision: Human Genome Sciences'(HGSI_) Zalbin for hepatitis C.
Oct. 8-12
European Society for Medical Oncology annual meeting. Data presentations to include Johnson & Johnson(JNJ) (abiraterone), Oxigene(OXGN_) (Zybrestat), Seattle Genetics (SGN-75), Allos Therapeutics(ALTH_) (Folotyn) and Arqule(ARQL_) (ARQ197).
The Obesity Society annual meeting. Stocks of interest include Arena Pharmaceuticals(ARNA_), Vivus(VVUS_) and Orexigen Therapeutics(OREX_).
Oct. 11
FDA drug approval decision: Alexza Pharmaceuticals'(ALXA_) AZ-004 for agitation in patients with schizophrenia or bipolar disorder.
FDA drug approval decision: Jazz Pharmaceuticals'(JAZZ_) JZP-6 for fibromyalgia.
Oct. 12
FDA drug approval decision: Alkermes(ALKS_) Vivitrol for opioid addiction.
Oct 13-16
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Data presentations to include Sanofi-Aventis(SNY_) (Teriflunomide), Biogen Idec(BIIB_) and Elan(ELN_) (Tysabri) and Genzyme(GENZ_) (Campath).
Oct. 18
FDA advisory panel to discuss the use of erythropoeisis-stimulating agents in the treatment of patients with chronic kidney failure. Amgen(AMGN_) (Aranesp, Epogen), Johnson & Johnson (Procrit) and Affymax(AFFY_) (Hematide).
Oct. 19
BioMarin Pharmaceuticals(BMRN_) analyst/investor day.
Oct. 20
Genzyme third-quarter earnings announcement.
Oct. 22
FDA drug approval decision: Arena Pharmaceuticals'(ARNA) lorcaserin for obesity
FDA drug approval decision: Amylin Pharmaceuticals(AMLN_), Alkermes and Eli Lilly's(LLY_) Bydureon for diabetes.
Oct. 28
FDA drug approval decision: Vivus'(VVUS) Qnexa for obesity.
Oct. 29
FDA drug approval decision: Avanir Pharmaceuticals'(AVNR_) Zenvia for pseudobulbar affect.
FDA drug approval decision: Forest Labs(FRX_) ceftaroline for Community Acquired Pneumonia. Oct. 30
FDA drug approval decision: Biodel's(BIOD_) Linjeta for diabetes.
Exact Sciences(EXAS_) presentation of external validation study of its genetic stool test for colon cancer.
